Pembrolizumab for Early Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. RESULTS: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improvement in overall survival has been reported in unresectable NSCLC patients and TNBC patients treated with anti PD-L1 antibody with chemotherapy”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Schmid et al., 2020
In the citing paper
“Immune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has shown promising results in TNBC4–6, but the overall response rate of ICB is less than 20%7.”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citation
Research works printed but not linked: 1
- Qi C Huang M Haiderali A et al. Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy. Presented at the NCCN Annual Conference Orlando March 21–23 2019.
Cited by
Items 701–800 of 1,004
Blaye, C., Darbo, É., Debled, M., Brouste, V., Velasco, V., Pinard, C., Larmonier, N., Pellegrin, I., Tarricone, A., Arnedos, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100502 · Cited by 26
Uchimiak, K., Badowska-Kozakiewicz, A. M., Sobiborowicz, A., & Deptała, A. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221099869 · Cited by 27
Pilewskie, M. L., Sevilimedu, V., Eroglu, I., Le, T., Wang, R., Morrow, M., & Braunstein, L. Z. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12193-w · Cited by 23
Zhang, M., Song, J. H., Yang, H., Jin, F., & Zheng, A. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2106795 · Cited by 29
“From the included literature, the NeoTRIPaPDL1 trial [21] indicated that the combination of atezolizumab, carboplatin, and nab-paclitaxel did not improve pCR rates, while IMpassion031 and KEYNOTE-522 showed positive results [22,24].”
BackgroundGazińska, P., Milton, C. K., Iacovacci, J., Ward, J., Buus, R., Alaguthurai, T., Graham, R. A., Akarca, A. U., Lips, E. H., Naidoo, K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0543 · Cited by 25
Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
Kiasari, B. A., Abbasi, A., Darestani, N. G., Adabi, N., Moradian, A., Yazdani, Y., Hosseini, G. S., Gholami, N., & Janati, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109365 · Cited by 31
Yuan, L., Liu, J., Bao, L., Qu, H., Xiang, J., & Sun, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1032364 · Cited by 23
“Although the results of the IMpassion130 and KEYNOTE-522 studies show that immunotherapy can significantly affect TNBC patients, the overall improvement in their prognosis remains suboptimal following treatment (38, 39).”
ResultTargeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
Mukherjee, D., Previs, R. A., Haines, C., Abo, M. A., Juras, P. K., Strickland, K. C., Chakraborty, B., Artham, S., Whitaker, R. S., Hebert, K. L., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1622 · Cited by 28
“The immunecheckpoint inhibitor pembrolizumab [anti-programmed cell death protein-1 (PD-1) monoclonal antibody] was recently approved for use in high-risk, early-stage TNBC, in combination with neoadjuvant chemotherapy and as a single agent in the adjuvant setting postsurgery (73).”
BackgroundZheng, C., Liu, Y., Wang, X., Bi, Z., Qiu, P., Qiao, G., Bi, X., Shi, Z., Zhang, Z., Chen, P., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000001011 · Cited by 24
“In KEYNOTE-522 study, pembrolizumab combined with the chemotherapy of carboplatin followed by anthracycline/cyclophosphamide demonstrated a pCR rate of 64.8% in early TNBC, with known safety pro fi les of platinum-containing neoadjuvant chemotherapy [3] .”
BackgroundMethodInfluentialPredicting Neoadjuvant Treatment Response in Triple-Negative Breast Cancer Using Machine Learning
Bhattarai, S., Saini, G., Li, H., Duanmu, H., Seth, G., Fisher, T. B., Janssen, E. A. M., Kiraz, U., Kong, J., & Aneja, R. (2023) · Diagnostics · doi:10.3390/diagnostics14010074 · Cited by 28
“A small subset of patients respond to newer therapies such as poly (ADP-ribose) polymerase inhibitors and immunotherapy [4].”
BackgroundRao, X., Qiao, Z., Yang, Y., Deng, Y., Zhang, Z., Yu, X., & Guo, X. (2024) · Pharmaceuticals · doi:10.3390/ph17020225 · Cited by 30
“Key clinical trials such as KEYNOTE-086 [8,9], IMpassion130 [10,11], and KEYNOTE-355 [12,13] have explored the therapeutic potential of PD-1 inhibitors such as pembrolizumab in metastatic TNBC, revealing significant improvements in patient prognosis.”
BackgroundConte, B., Brasó‐Maristany, F., Hernández, A. R., Pascual, T., Villacampa, G. J., Schettini, F., Vidal, M. J., Seguí, E., Angelats, L., García-Fructuoso, I., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105043 · Cited by 28
Lin, M., Kang, Y., & Zhang, X. F. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1410017 · Cited by 29
Houvenaeghel, G. F., de Nonneville, A. T., Cohen, M., Sabiani, L., Buttarelli, M., Charafe‐Jauffret, E., Jalaguier-Coudray, A., Bannier, M., Tallet, A. R., Viret, F., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.6930 · Cited by 21
“13,14 Accordingly, the use of NAC in these subtypes should rapidly increase and become dominant, even in patients with relatively low tumor burden.”
BackgroundMyers, S. P., Sevilimedu, V., Barrio, A. V., Tadros, A. B., Mamtani, A., Robson, M. E., Morrow, M., & Lee, M. K. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00674-y · Cited by 27
“Future investigations are needed to determine how changes to standard NAC regimens will contribute to differences in pCR between BRCA1/2 carriers and noncarriers, especially in those with TNBC who now receive chemoimmunotherapy given the fi ndings of KEYNOTE-522 29 .”
BackgroundRached, L., Peyre-Pradat, F., Spotti, M., Baldini, C., Laparra, A., Lambotte, O., Sakkal, M., Perret, A., Viansone, A. A., Michiels, S., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100061 · Cited by 34
Jayan, A., Sukumar, J. S., Fangman, B. D., Patel, T. A., Raghavendra, A. S., Liu, D. D., Pasyar, S., Rauch, R. A., Basen‐Engquist, K., Tripathy, D., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00371 · Cited by 33
Sugiyama, K., Gordon, A., Popat, S., Okines, A. F. C., Larkin, J., & Chau, I. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104122 · Cited by 30
“This pivotal randomised phase III trial evaluated the addition of pre-and post-operative pem-brolizumab to standard multiagent chemotherapy for stage 2-3 TNBC, 1 demonstrating the superiority of immuno-chemotherapy over chemotherapy in terms of both co-primary endpoints: pCR and EFS.”
Abraham, J., O’Connor, L. O., Grybowicz, L., Pinilla, K., Dayimu, A., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59151-0 · Cited by 29
“The PARTNER trial did not include immunotherapy 30 and thereforeavoids the multipleshort-and long-term toxicities associated with such treatments that are seen in early-stage breast cancer patients.”
Meyer, L., Jackson, H. W., Eling, N., Zhao, S., Usui, G., Dakhli, H., Schraml, P., Dettwiler, S., Elfgen, C., Varga, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.019 · Cited by 32
Ren, Y., Deng, R., Zhang, Q., Li, J., Han, B., & Ye, P. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6873 · Cited by 24
New Treatment Strategies for the Inflammatory Breast Cancer
Vagia, E., & Cristofanilli, M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00843-2 · Cited by 24
Tolba, M. F., Elghazaly, H. A., Bousoik, E., Elmazar, M. M., & Tolaney, S. M. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02613-w · Cited by 24
Ren, S., Xu, A., Lin, Y., Camidge, D. R., Maïo, M. D., Califano, R., Hida, T., Rossi, A., Guibert, N. M., Zhu, C., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-259 · Cited by 26
Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
Zhang, W., Kong, X., Ai, B., Wang, Z., Wang, X., Wang, N., Zheng, S., Fang, Y., & Wang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.582664 · Cited by 30
Jian, Y., Kong, L., Xu, H., Shi, Y., Huang, X., Zhong, W., Huang, S., Li, Y., Shi, D., Xiao, Y., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.725 · Cited by 21
Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer
Wan, Q., Zeng, Z., Qi, J., Chen, Z., Liu, X., & Zu, Y. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.004 · Cited by 23
Ou-Yang, F., Li, C.-L., Chen, C., Shen, Y.-C., Moi, S., Luo, C.-W., Xia, W.-Y., Wang, Y., Lee, H., Wang, L., et al. (2022) · PubMed · Cited by 28
Sex Hormones in Breast Cancer Immunity
Hargrove-Wiley, E., & Fingleton, B. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1829 · Cited by 25
Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?
Montero, A., & Ciérvide, R. (2022) · Current Oncology · doi:10.3390/curroncol29120768 · Cited by 23
PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
Tang, Q., Zhao, S., Zhou, N., He, J., Zu, L., Liu, T., Song, Z., Chen, J., Peng, L., & Xu, S. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5497 · Cited by 32
“irAEs occurred in 39% of patients, including grade 3 irAEs in 13% (32).”
BackgroundElmakaty, I., Abdo, R., Elsabagh, A. A., Elsayed, A., & Malki, M. I. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02941-7 · Cited by 25
“Pathologic complete response The number of patients who achieved a complete response was reported in six trials [36, 39, 41, 42, 44]: three on Atezolizumab [36, 39, 44], two on Pembrolizumab [41, 42], and one on Durvalumab [37], all in the neoadjuvant setting to chemotherapy.”
BackgroundMethodResultInfluentialAltena, R., Tzortzakakis, A., af Burén, S., Tran, T. A., Frejd, F. Y., Bergh, J. C. S., & Axelsson, R. (2023) · EJNMMI Research · doi:10.1186/s13550-023-00995-2 · Cited by 29
“Interestingly, PD-L1 status in the primary tumor has no therapy-predictive role for adding pembrolizumab to a chemotherapy backbone in the neoadjuvant treatment setting, as was observed in the Keynote-522 trial [4].”
ResultYu, J., Zhikun, G., & Wang, L. (2023) · Life · doi:10.3390/life13051189 · Cited by 24
“Although ICIs combined with neoadjuvant chemotherapy improves pCR and EFS in TNBC [28], only a subset of tumors responds to neoadjuvant ICI.”
BackgroundGreco, S., Fabbri, N., Spaggiari, R., Giorgi, A. D., Fabbian, F., & Giovine, A. (2023) · Biomedicines · doi:10.3390/biomedicines11061772 · Cited by 21
“[66], with their phase III trial KEYNOTE-522, even though this study was conducted on patients with stage II or III TNBC and not with a diagnosis of mTNBC.”
BackgroundNguyen, V. P., Campbell, K. M., Nowicki, T. S., Elumalai, N., Medina, E., Baselga-Carretero, I., DiNome, M. L., Chang, H. R., Oseguera, D. K., Ribas, A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0145 · Cited by 22
Liu, W.-L., Zhang, Y., Luo, X., Zhu, Y., Song, L., Ming, Z., Zhang, L.-X., Li, M.-J., Lv, R., Zhang, G., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s417944 · Cited by 24
“Pembrolizumab significantly improves OS rates when combined with chemotherapy when compared with controls in high combined positive score patients (CPS ≥ 10).(9,10) ICIs are promising strategies for improving current clinical TNBC”
BackgroundRogers, C., Cobb, A. N., Lloren, J. I., Chaudhary, L. N., Johnson, M. K., Huang, C., Teshome, M. K., Kong, A. L., Singh, P., & Cortina, C. S. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07114-8 · Cited by 23
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
Pescia, C., Guerini‐Rocco, E., Viale, G., & Fusco, N. (2023) · Cancers · doi:10.3390/cancers15225430 · Cited by 28
LeVee, A. A., Wong, M. H., Flores, S., Ruel, N. H., McArthur, H. L., Waisman, J. R., & Mortimer, J. E. (2024) · The Oncologist · doi:10.1093/oncolo/oyae064 · Cited by 30
Cerbelli, B., Scagnoli, S., Mezi, S., Luca, A. D., Pisegna, S., Amabile, M. I., Roberto, M., Fortunato, L., Costarelli, L., Pernazza, A., et al. (2020) · Cancers · doi:10.3390/cancers12092648 · Cited by 22
Han, Y., Wang, J., & Xu, B. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103376 · Cited by 24
Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative Treatments
Santos, E. S., Oliver, T. K., Lacchetti, C., Geisel, R. L., Wilfong, L. S., Fader, A. N., & Eng, C. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00545 · Cited by 21
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Baez‐Navarro, X., van den Ende, N. S., Nguyen, A. H., Sinke, R., Westenend, P. J., van Brakel, J. B., Stobbe, C., Westerga, J., & van Deurzen, C. H. M. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01783-z · Cited by 25
“Furthermore, a number of clinical trials have reported that the combination of immunotherapy (e.g., pembrolizumab or atezolizumab) and chemotherapy showed higher rates of pCR than chemotherapy alone [13, 14].”
BackgroundBreast Tumor-Bed Biopsy for Pathological Complete Response Prediction
Basik, M., Cecchini, R. S., Santos, J. D. L., Umphrey, H. R., Julian, T. B., Mamounas, E. P., White, J. R., Lucas, P. C., Balanoff, C., Tan, A. R., et al. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.1072 · Cited by 21
B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer
Stucchi, S., Borea, R., García‐Recio, S., Zingarelli, M., Rädler, P. D., Camerini, E., Pellegry, C. M., O’Connor, S., Earp, H. S., Carey, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011533 · Cited by 23
Corso, G., Shen, S., Criscitiello, C., Mukhtar, R. A., Gamble, L. A., Guerini‐Rocco, E., Pesapane, F., Nicosia, L., Jhaveri, K. L., Salimbeni, B. T., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103001 · Cited by 25
Mattavelli, G., Helal, M., Cetkovic, A., Krämer, M. J., Herbert, S.-L., Mielert, K., Schlaiß, T. N., Frank, A., Riemer, E., John, M., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.08.015 · Cited by 31
Alhudaithi, S. S., Almuqbil, R. M., Zhang, H., Bielski, E. R., Du, W., Sunbul, F. S., Bos, P. D., & da Rocha, S. R. P. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00983 · Cited by 24
Neoadjuvant immunotherapy in breast cancer: a paradigm shift?
Fountzila, E., & Ignatiadis, M. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1147 · Cited by 21
Adrada, B. E., Candelaria, R. P., Moulder, S. L., Thompson, A. M., Wei, P., Whitman, G. J., Valero, V., Litton, J. K., Santiago, L., Scoggins, M. E., et al. (2021) · Cancer · doi:10.1002/cncr.33604 · Cited by 21
Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials
Huynh, J. C., Patel, K. G., Gong, J., Cho, M. T., Malla, M., Parikh, A. R., & Klempner, S. J. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00893-6 · Cited by 20
Heitmeir, B., Deniz, M., Janni, W., Rack, B. K., Schochter, F., & Wiesmüller, L. (2022) · Cancers · doi:10.3390/cancers14040997 · Cited by 23
Zhang, X., Mu, X. L., Huang, O., Wang, Z., Chen, J., Chen, D., & Wang, G. (2022) · BMC Cancer · doi:10.1186/s12885-022-09286-w · Cited by 26
Blohmer, J., Link, T., Reinisch, M., Just, M., Untch, M., Stötzer, O. J., Fasching, P. A., Schneeweiß, A., Wimberger, P., Seiler, S., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.1059 · Cited by 23
Foldi, J., Kahn, A. M., Silber, A. L. M., Qing, T., Reisenbichler, E., Fischbach, N. A., Persico, J., Adelson, K. B., Katoch, A., Chagpar, A. B., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0862 · Cited by 22
Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis
Lin, Y., Gao, H., Yang, X., Zhu, T., Zheng, X., Ji, F., Zhang, L., Yang, C.-Q., Yang, M., Li, J., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.08.006 · Cited by 25
“In primary TNBC, PD-1 inhibitor combined with platinum-based neoadjuvant ChT produced significantly higher pCR rates across all subgroups [33,34].”
BackgroundStanowska, O., Kuczkiewicz‐Siemion, O., Dębowska, M., Olszewski, W. P., Jagiełło-Gruszfeld, A., Tysarowski, A., & Prochorec‐Sobieszek, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195524 · Cited by 23
“Furthermore, the duration of response to pembrolizumab was also prolonged with increased tumor PD-L1 expression, suggesting that the clinical benefit of pembrolizumab may be related to PD-L1 expression [3,22,23].”
BackgroundHurvitz, S. A., Bachelot, T., Bianchini, G., Harbeck, N., Loi, S., Park, Y. H., Prat, A., Gilham, L., Boulet, T., Gochitashvili, N., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0485 · Cited by 23
Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer
Kowalchuk, R. O., Niranjan, A., Hess, J. A., Antonios, J. P., Zhang, M. Y., Braunstein, S. E., Ross, R. B., Pikis, S., Deibert, C. P., Lee, C.-C., et al. (2022) · Journal of neurosurgery · doi:10.3171/2022.10.jns221900 · Cited by 21
Wong, C., Lam, T.-H., Liao, S.-Y., Lau, Y., Tse, H., & So, B. Y. F. (2023) · Biomedicines · doi:10.3390/biomedicines11010107 · Cited by 23
CD8+ T cell–Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance
Lao, L., Zeng, W., Huang, P., Chen, H., Jia, Z., Wang, P., Huang, D., Chen, J.-N., Nie, Y., Yang, L., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0356 · Cited by 22
Schreier, A., Zappasodi, R., Serganova, I. S., Brown, K. A., Demaria, S., & Andreopoulou, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1061789 · Cited by 26
“001) (10), leading to its FDA approval in this setting in July 2021 (10, 35, 42, 43).”
BackgroundStravokefalou, V., Stellas, D., Karaliota, S., Nagy, B. A., Valentin, A., Bergamaschi, C., DIMAS, K. S., & Pavlakis, G. N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1014802 · Cited by 26
“TNBC is more likely to show metastatic recurrence and patients with metastatic TNBC have higher mortality compared to patients with other breast cancer types (42.2% vs 28%, respectively) (4).”
BackgroundInfluentialZhao, M., Chen, S., Li, C., Du, Y., & Li, P. (2023) · Cancers · doi:10.3390/cancers15030600 · Cited by 25
Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature
Papatheodoridi, A. M., Papamattheou, E., Marinopoulos, S. S., Ntanasis‐Stathopoulos, I., Dimitrakakis, C., Giannos, A., Kaparelou, M., Liontos, M., Dimopoulos, M. A., & Zagouri, F. (2023) · Medical Sciences · doi:10.3390/medsci11020035 · Cited by 21
“Recently, the use of immunotherapy in the neoadjuvant setting has improved the rates of pathological complete response for triple-negative breast cancer [83].”
BackgroundMai, N., Abuhadra, N. K., & Jhaveri, K. L. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.05.012 · Cited by 28
The immunogram of inflammatory breast cancer
Valenza, C., Trapani, D., Fusco, N., Wang, X., Cristofanilli, M., Ueno, N. T., & Curigliano, G. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102598 · Cited by 22
Ligorio, F., Lobefaro, R., Fucà, G., Provenzano, L., Zanenga, L., Nasca, V., Sposetti, C., Salvadori, G., Ficchì, A., Franza, A., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34701 · Cited by 26
“21,23,24 In particular, we do not know if results of our study also apply to patients relapsing after exposure to more effective systemic therapies, such as neoadjuvant anthracycline-taxane-CBDCA chemotherapy plus pembrolizumab.”
BackgroundDupain, C., Gutman, T., Girard, E., Kamoun, C., Marret, G., Ajgal, Z. C., Sablin, M., Neuzillet, C., Borcoman, É., Hescot, S., et al. (2024) · BMC Biology · doi:10.1186/s12915-024-01839-8 · Cited by 30
“PD-L1 expression on tumor and/or immune cells using immunohistochemistry has been demonstrated to correlate with ICI efficacy in different cancer types [1–5].”
BackgroundLim, B., Seth, S., Yam, C., Huo, L., Fujii, T., Lee, J., Bassett, R. L., Nasser, S., Ravenberg, L., White, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101595 · Cited by 31
Zhou, J., Bai, Y., Zhang, Y., Wang, Z., Sun, S., Lin, L., Gu, Y., & You, C. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00746-z · Cited by 23
“This facilitates the identification of patients in whom pCR may not be achieved and the need for early adjustment of treat-ment, such as in combination with immunotherapy [40, 41] or bevacizumab [42], to increase the likelihood of achieving pCR and ultimately improve prognosis.”
BackgroundKrishnan, J., Patel, A., Roy, A. M., Alharbi, M., Kapoor, A., Yao, S., Khoury, T., Hong, C., Held, N. M., Chakraborty, A., et al. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.08.005 · Cited by 24
Brabo, E. P., Moraes, A. B., & Neto, L. V. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01306-5 · Cited by 25
A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer
Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 25
Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi, J., Rozenblit, M., Park, T. S., Knowlton, C. A., Golshan, M. A., Moran, M. S., & Pusztai, L. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00879-4 · Cited by 21
Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype
Jézéquel, P., Lasla, H., Gouraud, W., Basseville, A., Michel, B., Frenel, J., Juin, P. P., Azzouz, F. B., & Campone, M. (2024) · Breast Cancer · doi:10.1007/s12282-024-01597-z · Cited by 24
“However, one key problem for ICB resides in the identification of specific biomarkers for prediction of response to immune checkpoint (IC) inhibitors since PD-L1 expression, measured by immunohistochemistry (IHC), was reported as an imperfect ICB biomarker [3, 4].”
Divide and Conquer—Targeted Therapy for Triple-Negative Breast Cancer
Nedeljković, M., Vuletić, A. M., & Martinović, K. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041396 · Cited by 25
Chen, Y., Huang, Y., Li, W., Zhu, T., Cheng, M., Wu, C., Zhang, L., Peng, H., & Wang, K. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06369-7 · Cited by 26
Ebrahim, N. A. A., Hussein, M. A., Sobeih, M. E., & Amin, N. H. (2025) · BMC Cancer · doi:10.1186/s12885-025-14402-7 · Cited by 20
“However, in the malignant setting of TNBC, its aberrant overexpression disrupts these functions, driving enhanced cellular proliferation, invasion, and resistance to apoptosis [9, 31–36].”
Chen, D. H., Tyebally, S. M., Mallouppas, M., Roylance, R. R., Spurrell, E. L., Raja, F. A., & Ghosh, A. K. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01446-x · Cited by 24
Novel immune targets for the treatment of triple-negative breast cancer
Corti, C., Nicolò, E., & Curigliano, G. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2006187 · Cited by 21
Huo, X., Shen, G., Liu, Z., Liang, Y., Li, J., Zhao, F., Ren, D., & Zhao, J. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103530 · Cited by 22
Ma, S. J., Serra, L. M., Yu, B., Farrugia, M. K., Iovoli, A. J., Yu, H., Yao, S., Oladeru, O. T., & Singh, A. K. (2022) · Cancers · doi:10.3390/cancers14030534 · Cited by 20
Hoffmann, O., Wormland, S., Bittner, A., Collenburg, M., Horn, P. A., Kimmig, R., Kasimir‐Bauer, S., & Rebmann, V. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03980-9 · Cited by 22
A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy
Hu, D., Zhang, W., Xiang, J., Li, D., Chen, Y., Yuan, P., Shao, S., Zhou, Z., Shen, Y., & Tang, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100284 · Cited by 23
“This is an open access a activate the immune microenvironment and promote immune responses [7,8].”
BackgroundIn vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
Cheng, G. J., Leung, E. Y., & Singleton, D. C. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00084 · Cited by 22
Regulation of in vivo fate of exosomes for therapeutic applications: New frontier in nanomedicines
Park, J. H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.058 · Cited by 21
Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
Marron, T. U., Schwartz, M., Corbett, V., & Mérad, M. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s340935 · Cited by 23
Meraviglia-Crivelli, D., Zheleva, A., Barainka, M., Moreno, B., Villanueva, H., & Pastor, F. (2022) · Biomedicines · doi:10.3390/biomedicines10081842 · Cited by 20
“This was successfully employed as monotherapy for different types of tumors such as breast, urothelial and gastric cancers [5,48,49] or in combination with other treatments such as chemotherapy [50].”
MethodTumor immune microenvironment and systemic response in breast cancer
Kawaguchi, K., Maeshima, Y., & Toi, M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01782-0 · Cited by 22
“A recent study showed that BC cells can hijack the mitochondria from immune cells via physical nanotubes, and inhibiting the nanotube T cells of the same clone as tumour-infiltrating T cells are also found in the peripheral blood [9] Monocytes and macrophages are increased in the in PBMCs of BC patients [10] Various i…”
BackgroundInfluentialNicolini, A., Ferrari, P., & Carpi, A. (2022) · Biomedicines · doi:10.3390/biomedicines10102511 · Cited by 20
Takada, M., Yoshimura, M., Kotake, T., Kawaguchi, K., Uozumi, R., Kataoka, M., Kato, H., Yoshibayashi, H., Suwa, H., Tsuji, W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-27048-3 · Cited by 21
Zhou, H., Jia, W., Lu, L., & Han, R. (2023) · Cancers · doi:10.3390/cancers15030824 · Cited by 22
“However, the thera‐ peutic effect of PD‐1/PD‐L1 inhibitor monotherapy for breast cancer is limited, resulting in more attention on the multiple immune checkpoint blockade therapeutic strategy [62,63].”
BackgroundValenza, C., Rizzo, G., Passalacqua, M. I., Boldrini, L., Corti, C., Trapani, D., & Curigliano, G. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146129 · Cited by 23
Morganti, S., Bychkovsky, B., Poorvu, P. D., Garrido-Castro, A. C., Weiss, A. C., Block, C. C., Partridge, A. H., Curigliano, G., Tung, N., Lin, N., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad123 · Cited by 25
Valdivia, G., Alonso‐Miguel, D., Alenza, M. D. P., Zimmermann, A. B. E., Schaafsma, E., Kolling, F., Barreno, L., Alonso‐Diez, Á., Beiss, V., de Oliveira, J. F. A., et al. (2023) · Cells · doi:10.3390/cells12182241 · Cited by 24
“Although anti-PD-1 immunotherapy has been useful in treating some BC patients, it is only approved for early high-risk and advanced TN BC patients; only a minority of these patients benefit from this therapy [9–11].”
BackgroundCunha, M. T., Gouveia, M. C., Neto, F. L., Testa, L., Hoff, P. M., de Azambuja, E., & Bonadio, R. C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02501-w · Cited by 19
Recent Advances in Immunotherapy for Breast Cancer: A Review
Wen, Q.-E., Li, L., Feng, R.-Q., Li, D., Qiao, C., Xu, X., & Zhang, Y.-J. (2024) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s482504 · Cited by 28
Shigematsu, H., Fujisawa, T., Shien, T., & Iwata, H. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa055 · Cited by 21
Metadata
- Authors
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., Dent, R., & O’Shaughnessy, J.
- Affiliations
- Queen Mary University of London (GB)
- IOB Institute of Oncology, Quiron Group;Vall d’Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain
- Yale Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Kliniken Essen-Mitte (DE)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Samsung Medical Center (KR)
- The University of Sydney (AU)
- Ludwig-Maximilians-Universität München (DE)
- Sapporo National Hospital (JP)
- Universitätsklinikum Erlangen (DE)
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Helios Hospital Berlin-Buch (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National University of Singapore (SG)
- Baylor University Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 810-821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3006930853
- Cited by
- 3,270
- References
- 31
- Citations by year
- 2026: 580 · 2025: 576 · 2024: 552 · 2023: 500 · 2022: 514 · 2021: 391 · 2020: 152
- FWCI
- 133.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pembrolizumab, triple-negative breast cancer, early breast cancer, neoadjuvant immunotherapy, neoadjuvant chemotherapy, paclitaxel, carboplatin, pathological complete response, event-free survival, immune checkpoint inhibitors, doxorubicin-cyclophosphamide, epirubicin-cyclophosphamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Middle Aged, Neoplasm Staging, Epirubicin, Carboplatin, Paclitaxel, Neoadjuvant Therapy, Kaplan-Meier Estimate, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.